No­vo Nordisk is still play­ing catch up as We­govy de­mand rock­ets up­ward

We­govy de­mand con­tin­ues to sky­rock­et and No­vo Nordisk is still be­hind on meet­ing it, the com­pa­ny said as it un­veiled soar­ing sales in the third quar­ter of 2023.

“Un­der­ly­ing de­mand will con­tin­ue to out­pace sup­ply in the short to medi­um term,” said CEO Lars Fruer­gaard Jør­gensen on a me­dia call Thurs­day morn­ing.

In the first three quar­ters of 2023, over­all sales of the weight loss drug We­govy reached DKK 21.8 bil­lion ($3.1 bil­lion), com­pared to the DKK 3.7 bil­lion ($533.1 mil­lion) achieved in the first nine months of 2022, a growth of 481%. Be­tween Jan. 1 and Sept. 30 this year, sales of No­vo’s GLP-1 di­a­betes drugs grew by 45%, or 49% at con­stant ex­change rates (CER), and obe­si­ty care grew by 167% to DKK 30.4 bil­lion ($4.3 mil­lion), or 174% at CER – caus­ing the com­pa­ny to raise its over­all 2023 out­look.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER